AI Drug Discovery for Pharma and Biotech

Drug discovery

5

drugs

With orphan designations

Overview

IgG4-related disease (IgG4-RD) is a rare immune-mediated fibroinflammatory disorder characterized by tumor-like lesions, lymphoplasmacytic infiltrates rich in IgG4+ plasma cells, storiform fibrosis, and obliterative phlebitis. It affects multiple organs, including the pancreas, biliary tract, salivary glands, and kidneys, often mimicking malignancies or other systemic diseases. Diagnosis requires histopathology and elevated serum IgG4 (though nonspecific), with early glucocorticoid treatment critical to prevent irreversible fibrosis [1][3][18]. Relapses occur in ~40% of patients within 1 year [3][7].

Population

  • Primarily affects middle-aged to elderly adults (mean age 56–67 years), with male predominance (M:F 2–4:1); incidence rising to 1.39/100,000 person-years in the US [2][6][9]

  • Geographic variability: Higher reported prevalence in Japan; multi-organ involvement in 60–90% of cases [5][14][19]

Burden

  • Mortality rate 3.42/100 person-years (2.5× higher than general population) [2][6]

  • 24–40% relapse rate necessitates prolonged immunosuppression, increasing toxicity risks [3][7][15]

  • Undiagnosed cases risk irreversible organ damage (e.g., pancreatic insufficiency, renal failure) [4][14][17]

Therapies

  • First-line: Glucocorticoids (0.6 mg/kg prednisone for 2–4 weeks, tapering over 3–6 months) [3][7][10]

  • Relapse management: Rituximab (B-cell depletion), steroid-sparing immunosuppressants (azathioprine, mycophenolate), or surgery for obstructive complications [3][16][20]

  • Emerging: Targeted biologics (anti-CD19/20, BTK inhibitors) in clinical trials [10][16]

Categories: rare systemic and rheumatological diseases

Research Papers

1,443 drug discovery papers about IgG4-related disease, with 2 first-in-class and 26 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:

1,443 drug discovery papers about IgG4-related disease, with 2 first-in-class and 26 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:

categories:

Small molecules

small molecules
2026-09-26 | Isolated pulmonary IgG4-related disease mimicking infection and malignancy: clinical features and a proposed diagnostic approach.

IgG4-related lung disease (IgG4-RLD) is a rare manifestation that often presents with nonspecific clinical and radiological findings, frequently mimicking pulmonary infection or malignancy. This case series aimed to characterize the clinical, serological, radiological, and pathological features of isolated pulmonary IgG4-RLD and to identify features that may facilitate its differentiation from pulmonary infection and malignancy. We reviewed a case series of patients with isolated pulmonary IgG4-RLD diagnosed at the First Affiliated Hospital of Wenzhou Medical University between April 2014 and March 2025. Clinical characteristics, laboratory findings, chest computed tomography (CT) features, histopathological findings, treatment, and follow-up data were analyzed. Eight patients with isolated pulmonary IgG4-RLD were identified. All initially presented with nonspecific respiratory symptoms and were misdiagnosed as having other pulmonary diseases, most commonly pulmonary infection. Serum IgG4 concentrations were elevated in all patients, whereas microbiological investigations and serum tumor markers were negative. Radiologically, four patients presented with solitary pulmonary lesions that frequently mimicked lung malignancy, while the remaining four had multiple lesions suggestive of pulmonary infection. Histopathological examination revealed characteristic features of IgG4-RLD, supporting the diagnosis. Following glucocorticoid-based therapy, five of six treated patients showed radiological improvement, accompanied by decreased serum IgG4 levels, while one patient remained radiologically stable during follow-up. Isolated pulmonary IgG4-RLD may mimic pulmonary infection or malignancy because of its nonspecific clinical and radiological features. Solitary lesions may raise suspicion for lung malignancy, whereas multiple lesions may be mistaken for pulmonary infection. Diagnosis requires integration of clinical, serological, radiological, and histopathological findings, with tissue biopsy playing an important role when malignancy or infection cannot be reliably excluded. Key Points • Isolated pulmonary IgG4-RLD presents with nonspecific clinical manifestations and diverse radiological features, frequently mimicking pulmonary infection or lung malignancy. • Elevated serum IgG4 levels, negative microbiological investigations, and normal tumor markers may provide important diagnostic clues in patients with suspected disease. • Histopathological examination remains the cornerstone for confirming the diagnosis of isolated pulmonary IgG4-RLD. • Recognition of the characteristic clinical, serological, radiological, and pathological features may improve the differential diagnosis.

Open article ↗



2026-09-17 | Tofacitinib for the treatment of recurrent IgG4-related disease: clinical experience in 7 patients.

This observational study aimed to evaluate the efficacy and safety of the Janus kinase (JAK) inhibitor tofacitinib in the management of recurrent IgG4-related disease (IgG4-RD). Seven patients admitted to the Rheumatology Department of Peking University People's Hospital were enrolled. All patients met the 2019 American College of Rheumatology (ACR) / European League Against Rheumatism (EULAR) classification criteria for IgG4-RD. Disease recurrence was defined as relapse of previously affected organs or involvement of new organs, accompanied by an IgG4-RD Responder Index (IgG4-RD RI) score ≥2 in any item, with or without re-elevation of serum IgG4 levels. Patients were initiated on tofacitinib 5 mg twice daily, with a concurrent increase in glucocorticoids (GCs) dosage not exceeding 10 mg (prednisone equivalent), concomitant immunosuppressants were either continued or discontinued. Clinical data were recorded at baseline, 1 month, 3 months, and every 3 months thereafter. Disease response was assessed using the IgG4-RD RI, physician global assessment (PGA) and serum IgG4 levels. Treatment responses were categorised as complete response (CR), partial response (PR), or relapse. Patients were aged 33-70 years (mean disease duration, 45 months, range 18-84 months). Six patients achieved CR, while one experienced relapse. Tofacitinib treatment for 1, 3, and 6 months resulted in a reduction in both IgG4-RD RI scores (p=0.017, p=0.018, p=0.043, respectively) and PGA scores (p=0.017, p=0.018, p=0.042, respectively). Serum IgG4 levels decreased at 3 months (p=0.028) and 6 months (p=0.043). Within 6 months of initiating tofacitinib, four out of seven patients reduced their GC dosage to ≤5 mg/day (prednisone equivalent), and two discontinued GCs during follow-up. Tofacitinib was well tolerated. Only one patient developed mild herpes zoster, and no serious adverse events were reported. Tofacitinib is effective and safe for the management of recurrent IgG4-RD, with the additional benefit of reducing GC dependence.

Open article ↗



2026-09-13 | Efficacy and safety of mycophenolate mofetil in preventing relapse of IgG4-related disease with re-elevation of serum IgG4 level during maintenance therapy: a protocol for a multicentre, randomised, double-blind, placebo-controlled study in China.

IgG4-related disease is a chronic fibroinflammatory disease with multiorgan involvement. Glucocorticoids and/or immunosuppressants as well as rituximab are both first-line treatments in remission induction therapy. However, relapse is common during the maintenance period, particularly in patients with re-elevation of serum IgG4 level. This study aims to evaluate whether adding mycophenolate mofetil (MMF) during the maintenance phase for such patients can reduce the risk of disease flare. This study is a multicentre, randomised, double-blind, placebo-controlled study. A total of 108 eligible patients with re-elevation of serum IgG4 level during maintenance therapy will be included in this study and randomised in a 1:1 ratio to receive add-on MMF 0.5 g one time per day or placebo for 52 weeks. The primary outcome is the proportion of patients experiencing relapse at week 52. Secondary outcomes include time-to-relapse, changes in disease activity and serum IgG4 level, stratified relapse rate according to the elevation level of IgG4. Analyses will follow the intention-to-treat principle. The study has been approved by the Ethics Committee of Peking Union Medical College Hospital, Chinese Academy of Medical Sciences (approval no. K3231). Written informed consent will be obtained from all participants before enrolment. Findings will be disseminated through peer-reviewed journals and conference presentations. NCT05974683.

Open article ↗



2026-09-06 | Acute coronary syndrome associated with probable immunoglobulin G4-related coronary periarteritis successfully treated with a drug-coated balloon.

Immunoglobulin G4-related disease (IgG4-RD) is a systemic inflammatory disorder that can rarely affect the coronary arteries, leading to acute coronary syndrome (ACS). A 68-year-old man with IgG4-RD presented with exertional chest pain. An electrocardiogram showing ST-segment elevation in II, III, aVF leads, and rising troponin levels confirmed ACS. Emergent coronary angiography (CAG) revealed right coronary artery occlusion, and intravascular ultrasound (IVUS) showed vasculitis-related coronary pathology. Based on these findings and the patient's clinical background, ACS secondary to IgG4-related coronary periarteritis (IgG4-related CP) was diagnosed. Because stent implantation for inflammation-associated lesions carries a high risk of restenosis, percutaneous coronary intervention (PCI) without stenting was performed. Plaque ablation was achieved using excimer laser coronary atherectomy, followed by angioplasty with a drug-coated balloon. Post-PCI coronary computed tomography angiography demonstrated perivascular soft tissue around the culprit lesion, suggestive of ongoing inflammation. Follow-up CAG and IVUS confirmed good patency without restenosis after intensification of steroid therapy. This case highlights the complexity of ACS secondary to IgG4-related CP. Coronary involvement in IgG4-RD remains under-recognized, necessitating a high index of suspicion and multimodal imaging for diagnosis. Although rare, immunoglobulin G4-related coronary involvement should be considered a potential cause of acute coronary syndrome. Awareness of this entity and a multidisciplinary, multimodality imaging-based approach, including serial coronary computed tomography and intravascular ultrasound to assess treatment response, are essential for optimal management. In cases with insufficient response to corticosteroids, additional immunosuppressive therapy may be required.

Open article ↗



2026-08-13 | Isolated IgG4-related lung disease: a case report.

IgG4-related disease (IgG4-RD) represents a chronic, immune-driven fibroinflammatory condition capable of affecting diverse organ systems; within this spectrum, pulmonary involvement (IgG4-RLD) remains comparatively uncommon. This case report outlines the clinical, imaging and pathological features of a patient with IgG4-related lung disease. We report a 60-year-old male patient with recurrent fever, chest pain, and cough with hemoptysis. Chest computed tomography (CT) initially showed right upper lobe lesions suggestive of pneumonia, but the patient failed to respond to multiple courses of antibiotics including levofloxacin, nemonoxacin malate, ceftizoxime, and amoxicillin. Further investigations revealed significantly elevated serum IgG4 level (266 mg/dL). Endobronchial ultrasound-guided transbronchial lung cryobiopsy (EBUS-GS-TBLC) confirmed dense lymphoplasmacytic infiltration in the lung tissue, with IgG4-positive plasma cells >50 per high powered field (HPF) and IgG4-positive/IgG-positive cell ratio >50%, consistent with the diagnosis of IgG4-related interstitial lung disease. The patient was treated with oral cyclosporine and mycophenolate mofetil, resulting in significant clinical and radiological improvement. IgG4-RLD should be considered in the differential diagnosis of patients with pulmonary lesions unresponsive to antibiotic therapy. Comprehensive evaluation including serum IgG4 measurement and targeted pathological biopsy is essential for accurate diagnosis. Early initiation of immunosuppressive therapy can effectively improve outcomes and prevent disease progression.

Open article ↗



antibodies
2026-09-24 | IgG4-to-IgG Ratio and Orbital Involvement Predict Clinical Response to B Cell Depletion in IgG4-Related Disease.

IgG4-related disease (RD) demonstrates ethnic variations in phenotype, but data from diverse US populations are limited. We characterized ethnic differences in organ involvement and evaluated predictors of treatment response in a multiethnic cohort. We conducted a retrospective study of 58 patients meeting 2019 American College of Rheumatology/EULAR criteria at Northwell Health (2011-2023). Data on demographics, organ involvement, histopathology, treatment, and serology (IgG4-to-IgG ratios) were analyzed. Response was assessed using Carruthers' Index. The cohort included 43.1% White, 24.1% Asian, 19.0% Hispanic, and 13.8% Black patients. Organ involvement patterns were consistent across races, with lymph nodes (22.4%), orbital/lacrimal (20.7%), and retroperitoneum (20.7%) being most affected. Higher disease burden was observed in Asian patients (1.93 vs 1.44-1.64 organs, P = 0.058). A striking disparity in rituximab use was observed (0% in Black patients vs 57%-76% in others, P = 0.002), whereas disease phenotype distribution was otherwise similar across groups. Favorable response rates were high and comparable across all racial and ethnic groups (78.6%-100%, P = 0.462). In patients treated with rituximab (n = 35), a reduction in IgG4-to-IgG ratio predicted response (area under the curve = 0.806), outperforming baseline ratios. Orbital/lacrimal involvement was strongly associated with treatment failure (75% of nonresponders vs 13.3% of responders; odds ratio 6.6, 95% confidence interval 1.4-31.9, P = 0.03). In a diverse IgG4-RD cohort, disease phenotypes were consistent across races, though treatment access disparities existed. Dynamic changes in IgG4-to-IgG ratios and the presence of orbital disease are key predictors of response to rituximab, informing personalized treatment strategies.

Open article ↗



2026-09-22 | A Rare Case of Gastritis with Prominent IgG4-Positive Plasmacytosis Mimicking IgG4-Related Gastrointestinal Disease.

IgG4-related disease (IgG4-RD) is a systemic fibroinflammatory condition characterized by dense infiltration of IgG4-positive plasma cells across multiple organs, with well-established comprehensive diagnostic criteria and organ-specific criteria. However, diagnostic standards for IgG4-related disease involving the digestive tract remain relatively new and less clearly defined. We report a case suspicious for IgG4-related gastrointestinal disease (IgG4-GID). Although a definitive diagnosis could not be established, the clinical course of the patient and our assessment based on the most up-to-date evidence warrant attention. A 40-year-old man was referred to our hospital after esophagogastroduodenoscopy revealed irregular nodules in the gastric mucosa, raising the suspicion of scirrhous-type gastric cancer. He had no significant medical history and had undergone successful eradication of Helicobacter pylori infection 5 years previously. Endoscopic examination revealed a faded shallow depression, irregular nodules, and converging folds in the gastric body. Magnifying endoscopy with narrow band imaging demonstrated a tree-like appearance with several irregular vessels, raising the suspicion of mucosa-associated lymphoid tissue (MALT) lymphoma, and a biopsy was performed. Laboratory tests showed that serum gastrin, anti-gastric parietal cell antibody, and IgG4 levels were within normal ranges. Histopathological examination showed no evidence of MALT lymphoma but revealed bottom-heavy plasmacytosis, and IgG4 immunostaining demonstrated an IgG4/IgG-positive cell ratio exceeding 40%. Endoscopic ultrasound revealed mucosal and submucosal thickening, and computed tomography (CT) showed thickening of the gastric wall, while positron emission tomography-CT showed no abnormal uptake. During the 5-year follow-up, no significant changes were observed. Biopsy also revealed neutrophilic infiltration in the superficial layer. Although IgG4-related gastritis was suspected clinically, neutrophil infiltration is uncommon in IgG4-related gastritis, and further differential diagnosis is required. This case highlights the diagnostic challenges of IgG4-rich gastric lesions and underscores the importance of distinguishing them from IgG4-GID and MALT lymphoma. When a definitive diagnosis cannot be established, careful long-term follow-up is warranted.

Open article ↗



2026-09-20 | Glucocorticoids combined with rituximab treatment for IgG4-related tubulointerstitial nephritis with diabetic nephropathy: a case report.

IgG4-related disease is a chronic immune-mediated disorder featuring elevated serum IgG4 levels and the tissue infiltration of IgG4-positive plasma cells. Kidney involvement in IgG4-related disease, known as IgG4-related kidney disease, most commonly manifests as tubulointerstitial nephritis. A 55-year-old male presented with acute kidney injury (creatinine=816 μmol/L), severe anemia, lymphadenopathy, and high IgG4 levels (13.89 g/L). Renal MRI and Chest CT showed diffuse renal abnormalities and mediastinal lymphadenopathy. Renal biopsy confirmed IgG4-related tubulointerstitial nephritis, complicated by IgA nephropathy and diabetic nephropathy. Initial glucocorticoid treatment was prescribed followed by 1.8 g rituximab consolidation therapy. Over 32 months follow-up, the patient's renal function significantly improved (creatinine 215 μmol/L) and his serum IgG4 levels normalized (0.89 g/L). This success of this case suggests that combination therapy may be a reasonable option in selected cases, and underscores the importance of an early diagnosis, pathological confirmation, and standardized immunosuppressive therapy for improving the outcomes in IgG4-related kidney disease.

Open article ↗



2026-09-15 | Diffuse Pericoronary Soft-Tissue Cuffing on Coronary Computed Tomography Angiography in a Patient with Unstable Angina: Possible IgG4-Related Coronary Periarteritis.

A 66-year-old man with hypertension, type 2 diabetes mellitus, and a 50-year smoking history was presented with acute chest pain clinically consistent with unstable angina. Coronary computed tomography angiography (CCTA) showed multivessel atherosclerosis and, more strikingly, diffuse sheath-like pericoronary soft-tissue cuffing around the major epicardial arteries-an appearance reported as the "mistletoe sign" and compatible with immunoglobulin G4 (IgG4)-related coronary periarteritis. CT-derived fractional flow reserve (CT-FFR) measured 0.75 in the left anterior descending artery, 0.68 in the left circumflex artery, and 0.94 in the right coronary artery. Invasive angiography identified a 90% proximal left circumflex stenosis as the flow-limiting lesion; drug-eluting stent implantation restored Thrombolysis in Myocardial Infarction (TIMI) grade 3 flow. Serum IgG4 (145 mg/dL) was only marginally above the diagnostic threshold, and troponin was unavailable, so the diagnosis remained clinical. Without histopathology, the findings support possible rather than definite IgG4-related disease, and the contribution of the pericoronary process to the stenosis could not be established. The patient remained stable on conventional medical therapy. CCTA, CT-FFR, and angiography answer complementary questions; diffuse pericoronary change warrants serologic and systemic evaluation for inflammatory coronary involvement, with cautious etiologic attribution.

Open article ↗



2026-08-28 | IgG4-related disease - treatment with anti-CD20, anti-CD19 antibodies, and other new drugs.

IgG4-related disease (IgG4-RD) can affect any tissue. Characteristic symptoms include tumor-like swelling of one or more organs, lymphadenopathy, involvement of the pancreatic and/or bile ducts, aortitis and retroperitoneal fibrosis, inflammatory swelling of the lacrimal or salivary glands, and nephropathy. Laboratory changes include hyperproteinemia, increased IgG4 concentration, eosinophilia, and elevated circulating plasmablasts. Presence of any of these symptoms should prompt a differential diagnosis focused on IgG4-RD. International recommendations for treatment of IgG4-RD were published in 2015, and since then, numerous studies and meta-analyses of new treatment approaches have been published. These indicate that, in 2026, the treatment of choice is monoclonal anti-CD20 antibodies, rituximab or obinutuzumab, or alternatively, the anti-CD19 antibody inebilizumab. Rituximab achieves a significantly higher number of treatment responses and has fewer side effects than the previously used prednisone, whether in monotherapy or in combination with oral immunosuppressants. However, even after rituximab treatment, the rate of early relapses is around 16-20%. Therefore, maintenance therapy with rituximab is recommended. Another approach to achieving a longer-lasting treatment response is the combination of rituximab with cyclophosphamide. In 2025, the anti-CD19 monoclonal antibody inebilizumab was approved in the United States and Europe for the treatment of IgG4-RD. It targets a broader range of B cells than rituximab and induces a longer-lasting therapeutic response. The efficacy of other drugs (obexelimab, abatacept, daratumumab, dupilumab, and others) is documented through case reports and small patient series or phase II clinical trials, and we are awaiting the results of phase III registration studies. Anti-CD20 and anti-CD19 antibodies represent the treatment of choice for IgG4-RD. They achieve a high number of complete treatment responses; however, the treatment does not end there, as it is necessary to prevent disease relapses, which are common without maintenance therapy.

Open article ↗



cell therapies
2026-01-27 | Effects of anti-CD19 CAR-T cells in a murine model of IgG4-related disease.

BACKGROUND: Chimeric antigen receptor T-cell (CAR-T) therapy, an emerging immunotherapy, has shown promising efficacy in several autoimmune diseases. In this study, we conducted a preclinical evaluation of the therapeutic potential of CD19-specific CAR-T cell–mediated B-cell depletion in a mouse model that recapitulates key features of human IgG4-related disease (IgG4-RD). METHODS: B cell depletion strategies were evaluated in the LatY136F mouse model, a spontaneous murine model of IgG4-RD. Anti-CD19 CAR-T cells or control cells were transferred into LatY136F mice pretreated with total body irradiation. LatY136F mice treated with anti-CD20 monoclonal antibodies (mAb) served as the positive control group. RESULTS: CD19-targeted CAR-T cell infusion resulted in a more profound depletion of B cells and plasmablasts compared to anti-CD20 mAb treatment. This depletion was observed in peripheral blood, spleen, lacrimal glands, lungs, and pancreas in LatY136F mice. Moreover, CAR-T cell therapy significantly prolonged the survival of LatY136F mice and improved clinical symptoms compared to anti-CD20 mAb treatment. However, while CAR-T cell therapy reduced inflammation and fibrosis in the lacrimal glands and pancreas, it did not improve these conditions in the lungs. CONCLUSIONS: Our findings demonstrate that anti-CD19 CAR-T therapy effectively alleviates the progression of IgG4-RD, showing superior efficacy compared to anti-CD20 mAb in this preclinical model. These results support further investigation of CAR-T cells as a potential therapeutic option for IgG4-RD patients, with attention to potential adverse effects.

Open article ↗



2025-12-11 | CAR T-cell therapy induces remission in multiorgan IgG4-related disease with hepatobiliary involvement.

IgG4-related disease (IgG4-RD) is a fibroinflammatory disorder in which IgG4+ B cells and T cells interact to drive chronic organ inflammation. Patients with multiorgan involvement may become refractory to standard therapy, resulting in progressive organ damage and risk of organ failure. Here, we report a patient with treatment-refractory multiorgan IgG4-RD treated with CD19-directed chimeric antigen receptor (CAR) T cells and describe the clinical and immunologic effects over more than 12 months of follow-up. A 60-year-old man with IgG4-RD involving the pancreas, hepatobiliary tract, and lungs, who was refractory to long-term immunosuppression, received autologous CD19-directed CAR T cells. Disease course was monitored longitudinally and multimodal immune profiling was performed on peripheral blood. CAR T cell therapy was well tolerated, with only grade 1 cytokine release syndrome, no neurotoxicity, and transient cytopenias without infections. Treatment induced B-cell aplasia lasting 6 months, while serum IgG4 levels normalized by month 8 and remained within the reference range thereafter. FAPI (fibroblast activation protein inhibitor) PET/CT demonstrated regression of fibroinflammatory activity, accompanied by improved lung function and quality of life. Immunosuppressive therapy was completely discontinued without disease flares for more than 12 months. B cell reconstitution consisted predominantly of naïve and transitional subsets. This was paralleled by a decline in T follicular helper cells and CD4+ cytotoxic T cells and attenuation of fibro-inflammatory and B cell-mediated signaling networks on interactome analyses. In this treatment-refractory case of multiorgan IgG4-RD, CD19-directed CAR T cell therapy induced durable, treatment-free remission with normalization of serum IgG4 and improvement across multiple clinical endpoints. Multimodal immune profiling indicates that CAR T cells can reset the B cell compartment and dampen pathogenic T cell and stromal interactions, supporting prospective evaluation of CAR T cell therapy in IgG4-RD.

Open article ↗



2025-09-20 | Heart Transplantation in Advanced Heart Failure Due to IgG4-Related Endomyocardial Fibrosis.

IgG4-related disease (IgG4-RD) is a systemic fibroinflammatory condition that rarely affects the heart. Cardiac manifestations include pericarditis, coronary arteritis, and myocarditis; endomyocardial fibrosis (EMF) is exceedingly rare. We report a 66-year-old man with advanced heart failure and recurrent hospitalizations due to restrictive cardiomyopathy, initially attributed to hypereosinophilia from parasitic disease. The patient developed cardiogenic shock requiring inotropes and intra-aortic balloon pump support. Imaging revealed biatrial enlargement, endocardial thickening, and subendocardial fibrosis, suggestive of EMF. Serology was positive for Trichinella spiralis IgG. Because of progressive clinical deterioration, the patient underwent urgent orthotopic heart transplantation. Histology of the explanted heart confirmed IgG4-related EMF. Posttransplant follow-up at 12 months showed preserved graft function and no recurrence. This case illustrates a rare cause of end-stage heart failure due to IgG4-RD and highlights the importance of including systemic inflammatory conditions in the differential diagnosis of restrictive cardiomyopathy. IgG4-related disease, though rare, can present as isolated endomyocardial fibrosis with features mimicking tropical EMF or hypereosinophilic cardiomyopathy. In advanced fibrotic stages with isolated cardiac IgG4-RD and cardiogenic shock, orthotopic heart transplantation may be the only lifesaving therapeutic option.

Open article ↗



2025-04-30 | Refractory corneal melting due to IgG4-related disease: Successful management via buccal mucosal graft transplantation.

PurposeTo present the first case of isolated corneal involvement in IgG4-RD, managed successfully with oral mucosal grafting due to the destructive course of the disease.Case reportA 56-year-old female one-eyed patient was referred to our clinic with a diagnosis of unresponsive infectious corneal melting. The ophthalmologic examination revealed light perception visual acuity, intense conjunctival inflammation and an infected area of approximately 4 × 5 mm with accompanying melting. Her medical history includes a diagnosis of dry eye disease that has persisted for over a decade, multiple previous corneal transplant surgeries in the right eye with similar complaints, and subsequent evisceration surgery. Her complaints in the left eye had increased over the previous six months, and she had undergone eight instances of amniotic membrane transplantation at an external medical facility. Corneal scraping, conjunctival and corneal biopsy were performed. The histopathologic examination and elevated serum IgG4 level indicated the presence of IgG4-related disease. She was referred to the rheumatology department, where immunosuppression treatment was initiated. Oral mucosal grafting was performed to address the uncontrolled melting. At the follow-up examination, the melting was successfully controlled, the inflammation regressed, and the early hypertrophy of the oral mucosal epithelium flattened over time.ConclusionThis case highlights the potential for IgG4-related disease to manifest as atypical ocular surface involvement. Dry eye secondary to the disease can exacerbate existing findings. In such instances, preserving the integrity of the globe is of the utmost importance. Therefore, oral mucosal grafting, which is known for its durability, should be considered a viable option.

Open article ↗



2024-12-14 | Efficacy and safety of anti-CD19 CAR-T in a mouse model of IgG4-related disease.

Dysregulated B-cell activation plays pivotal roles in IgG4-related disease (IgG4-RD), which makes B-cell depletion a potential strategy for IgG4-RD treatment. In this study, we aimed to investigate the feasibility of applying anti-CD19 chimeric antigen receptor T(CAR-T) cell therapy to IgG4-RD treatment in a mouse disease model based on LatY136F knock-in (Lat) mice. We constructed murine anti-CD19 CARs with either CD28 or 4-1BB as the intracellular costimulatory motif and evaluated the therapeutic function of the corresponding CAR-T cells by infusing them into Lat mice. Next, we assessed the safety of CAR-T infusion by evaluating the risk of cytokine release syndrome (CRS) and the antiviral capabilities in a mouse influenza infection model. Finally, we performed human anti-CD19 CAR-T manufacturing from IgG4-RD patients and evaluated its activation level and functional effects in vitro. Compared with 1D3 antibody treatment, the adoptive transfer of anti-CD19 CAR-T cells with CD28 costimulatory motif showed comparable B-cell-depletion effect in Lat mice. Furthermore, the transfer of syngeneic anti-CD19 CAR-T cells also decreased the percentage of plasma cells as well as IL-4 secreting Th cells, therefore attenuating the inflammation and fibrosis condition. CAR-T cells with CD28 costimulatory motif showed better therapeutic efficiency without the incidence of serious CRS events or increasing the risk of infection. In addition, we validated the feasibility of human CAR-T preparation in vitro from IgG4-RD patients. Taken together, these results show that anti-CD19 CAR-T therapy was effective in the treatment of a murine model of IgG4-RD, indicating its potential for clinical use in patients.

Open article ↗



proteins
2024-01-23 | Laminin 511-E8, an autoantigen in IgG4-related cholangitis, contributes to cholangiocyte protection


Abstract

Background & Aims

IgG4-related cholangitis (IRC) is the hepatobiliary manifestation of IgG4-related disease. Anti-laminin 511-E8 autoantibodies have been identified in its pancreatic manifestation. Laminin 511-E8 promotes endothelial barrier function, lymphocyte recruitment, and cholangiocyte differentiation. Here, we investigate anti-laminin 511-E8 autoantibody presence in IRC, and mechanisms via which laminin 511 may contribute to cholangiocyte protection.

Methods

Anti-laminin 511-E8 serum autoantibody positivity was assessed by ELISA. RNA sequencing and RT-qPCR were performed on human H69 cholangiocytes treated with recombinant laminin 511-E8. H69 cholangiocytes were subjected to shRNA knockdown targeting genes encoding laminin 511 (LAMA5, LAMB1, LAMC1) or treated with recombinant laminin 511-E8. Cholangiocellular bile acid influx was quantified radiochemically using 22,23-3H-glycochenodeoxycholic acid (GCDC). GCDC-induced apoptosis was determined by Caspase-3/7 assays. Cholangiocellular barrier function was assessed by FITC-dextran permeability assays. Immunofluorescent staining of laminin 511 and claudin 1 was performed on extrahepatic bile duct tissue of control and anti-laminin 511-E8 positive individuals with IRC.

Results

Seven out of 52 individuals with IRC had autoantibodies against laminin 511-E8. Recombinant laminin 511-E8 led to differential expression of genes involved in secretion, barrier function, and inflammation. Knockdown of laminin 511 constituents increased toxic bile acid permeation and GCDC-induced apoptosis. Laminin 511-E8 treatment decreased toxic bile acid permeation and dose-dependently alleviated GCDC-induced apoptosis. LAMA5 and LAMC1 knockdown increased transepithelial permeability. Laminin 511-E8 treatment reduced transepithelial permeability and prevented T lymphocyte-induced barrier dysfunction. Laminin 511 and claudin 1 staining patterns appeared altered in anti-laminin 511-E8 positive individuals with IRC.

Conclusions

Laminin 511-E8 is an autoantigen in subsets of individuals with IRC. Laminin 511 enhances cholangiocellular barrier function and protects cholangiocytes against T lymphocyte-induced barrier dysfunction, toxic bile acid permeation and bile acid-induced apoptosis.

Impact and implications

A subset of IgG4-related cholangitis (IRC) patients has autoantibodies against laminin 511-E8. In human cholangiocytes, laminin 511 protects against (T lymphocyte-induced) epithelial barrier dysfunction and hydrophobic bile acids. Laminin 511 and claudin 1 staining may be altered in extrahepatic bile ducts of anti-laminin 511-E8 positive IRC patients. This makes it tempting to speculate that a decreased epithelial barrier function with attraction of immune cells and impaired bicarbonate secretion due to dysfunction of laminin 511 by autoantibody binding could potentially be a common systemic pathogenetic mechanism in a subset of IgG4-RD patients.


Open article ↗



2022-05-19 | Role of eosinophilia in IgG4-related disease.

Immunoglobulin G4-related disease (IgG4-RD) is a heterogeneous immune-mediated condition that can affect almost any organ and is now being recognised with increasing frequency. Laboratory abnormalities including peripheral eosinophilia, hypergammaglobulinaemia, elevated serum IgE level, and hypocomplementaemia often provide initial clues to the diagnosis of IgG4-RD. The distinctive histopathological hallmarks of IgG4-RD are a dense lymphoplasmacytic infiltration with a high percentage of IgG4+ plasma cells, storiform fibrosis, obliterative phlebitis, and mild to moderate tissue eosinophilia. Around 20-40% of patients with IgG4-RD presented with peripheral eosinophilia and 51-86% are manifested as tissue eosinophilia. These data indicate an extensive involvement of eosinophil in IgG4-RD. Here, we review the biology of eosinophil, the discovery of eosinophilia in IgG4-RD, and its association with disease activity and relapse. We also discuss the possible functions and therapeutic potential of eosinophil in IgG4-RD.

Open article ↗



2022-05-13 | Central Diabetes Insipidus Due to IgG4-related Hypophysitis That Required over One Year to Reach the Final Diagnosis Due to Symptoms Being Masked by Sialadenitis

Pituitary inflammation due to IgG4-related disease is a rare condition and is sometimes accompanied by central diabetes insipidus. Central diabetes insipidus produces a strong thirst sensation, which may be difficult to distinguish when complicated by salivary insufficiency. A 45-year-old man was admitted to our department for a thorough examination of his thirst and polyuria. He had suddenly developed these symptoms more than one year earlier and visited an oral surgeon. Swelling of the left submandibular gland, right parotid gland, and cervical lymph nodes had been observed. Since his IgG4 level was relatively high at 792 mg/dL and a lip biopsy showed high plasmacytoid infiltration around the gland ducts, he had been diagnosed with IgG4-related disease. He had started taking 0.4 mg/kg/day of prednisolone, and his chief complaint temporarily improved. However, since the symptom recurred, he was referred to our institution. After admission, to examine the cause of his thirst and polyuria, we performed a water restriction test, vasopressin loading test, hypertonic saline loading test and pituitary magnetic resonance imaging. Based on the findings, we diagnosed him with central diabetes insipidus due to IgG4-related hypophysitis. We increased the dose of prednisolone to 0.6 mg/kg/day and started 10 μg/day of intranasal desmopressin. His symptoms were subsequently alleviated, and his serum IgG4 level finally normalized. We should remember that IgG4-related disease can be accompanied by hypophysitis and that central diabetes insipidus is brought about by IgG4-related hypophysitis. This case report should remind physicians of the fact that pituitary inflammation due to IgG4-related disease is very rare and can be masked by symptoms due to salivary gland inflammation, which can lead to pitfalls in the diagnosis in clinical practice.

Open article ↗



2022-03-03 | Neutralizing anti-IL-1 receptor antagonist autoantibodies induce inflammatory and fibrotic mediators in IgG4-related disease.

IgG4-related disease (IgG4-RD) is a fibroinflammatory condition involving loss of B-cell tolerance and production of autoantibodies. However, the relevant targets and role of these aberrant humoral immune responses are not defined. Our aim was to identify novel autoantibodies and autoantigen targets that promote pathogenic responses in IgG4-RD. We sequenced plasmablast antibody repertoires in patients with IgG4-RD. Representative mAbs were expressed and their specificities characterized by using cytokine microarrays. The role of anti-IL-1 receptor antagonist (IL-1RA) autoantibodies was investigated by using in vitro assays. We identified strong reactivity against human IL-1RA by using a clonally expanded plasmablast-derived mAb from a patient with IgG4-RD. Plasma from patients with IgG4-RD exhibited elevated levels of reactivity against IL-1RA compared with plasma from the controls and neutralized IL-1RA activity, resulting in inflammatory and fibrotic mediator production in vitro. IL-1RA was detected in lesional tissues from patients with IgG4-RD. Patients with anti-IL-1RA autoantibodies of the IgG4 subclass had greater numbers of organs affected than did those without anti-IL-1RA autoantibodies. Peptide analyses identified IL-1RA epitopes targeted by anti-IL-1RA antibodies at sites near the IL-1RA/IL-1R interface. Serum from patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) also had elevated levels of anti-IL-1RA autoantibodies compared with those of the controls. A subset of patients with IgG4-RD have anti-IL-1RA autoantibodies, which promote proinflammatory and profibrotic meditator production via IL-1RA neutralization. These findings support a novel immunologic mechanism underlying the pathogenesis of IgG4-RD. Anti-IL-1RA autoantibodies are also present in a subset of patients with SLE and RA, suggesting a potential common pathway in multiple autoimmune diseases.

Open article ↗



2021-10-13 | Interleukin-35 promotes the differentiation of regulatory T cells and suppresses Th2 response in IgG4-related type 1 autoimmune pancreatitis.

IgG4-related disease (IgG4-RD) is a systemic inflammatory disease, which includes type 1 autoimmune pancreatitis (AIP). Interleukin-35 (IL-35) exhibits immunosuppressive effects in several autoimmune diseases. However, the expression of IL-35 had not been reported so far in type 1 AIP. We evaluated the association between IL-35 and several cytokines, which mediate the function of Tregs in type 1 AIP. Plasma was collected from patients with type 1 AIP, alcoholic chronic pancreatitis (ACP), and healthy controls (HC) and assayed for cytokine expression. Total mRNA separated from peripheral blood was isolated from naïve Tregs (nTregs) and effector Tregs (eTregs). EBI3 and IL-12p35 gene expressions were tested in these cells by quantitative PCR. In addition, expression of IL-35 subunits in the pancreatic tissues of patients with type 1 AIP and ACP was analyzed by immunohistochemistry. IL-35 was significantly elevated in type 1 AIP (n = 32) plasma compared with ACP (n = 16) and HC (n = 22), but IL-27 was not. We also detected many cells expressing both EBI3 and IL-12p35 in type 1 AIP tissues. Moreover, in peripheral blood lymphocyte, the percentage of nTregs and eTregs of CD4+ T cells in patients with type 1 AIP (n = 14) compared with HC (n = 15) was significantly decreased and increased, respectively. There were no significant differences of gene expression in patients with type 1 AIP and HC. This study identified elevated expression of plasma IL-35 and tissue IL-35 subunits in patients with type 1 AIP. This might lead to inflammation suppression via activated eTregs. IL-35 might be associated with this anti-inflammatory role, especially against the Th2 response through several cytokines and the differentiation of Tregs in type 1 AIP.

Open article ↗



other
2025-07-08 | A case of IgG4-related disease potentially triggered by COVID-19 vaccination: longitudinal serum IgG4 monitoring from prevaccination.

We report a case of a 64-year-old Japanese man who developed IgG4-related pericoronary arteritis following mRNA-based COVID-19 vaccination. The patient presented with anterior chest pain and imaging revealed perivascular soft tissue thickening around the coronary arteries, along with pancreatic enlargement, enlarged prostate, and periaortitis. Laboratory tests showed markedly elevated serum IgG4 levels (1740 mg/dl). Histopathological findings from prostate biopsy were consistent with IgG4-related disease. Notably, retrospective analysis of preserved serum samples demonstrated a sharp increase in IgG4 levels following the third BNT162b2 vaccine dose, suggesting a possible link between vaccination and disease onset. The patient responded to prednisolone, with significant clinical and radiological improvement. However, IgG4 levels rebounded during tapering, requiring additional immunosuppressive therapy with azathioprine and planned rituximab treatment. This case represents the first documented instance tracking longitudinal changes in serum IgG4 levels from prevaccination through disease onset. While a definitive causal relationship between COVID-19 vaccination and IgG4-related disease remains unproven, this case highlights the need for further investigation into the potential immunopathogenic mechanisms involved.

Open article ↗



2023-10-02 | Suppressed IgG4 class switching in dupilumab- and TNF inhibitor-treated patients after repeated SARS-CoV-2 mRNA vaccination

Abstract Background Repeated mRNA vaccination against SARS-CoV-2 has been shown to induce class switching to IgG4, a non-inflammatory human antibody subclass linked to tolerance. Although poorly understood, prolonged antigenic stimulation and IL-4 signalling may be instrumental in IgG4 switching. We and others have previously shown that widely used immunosuppressive drugs such as methotrexate (MTX) and TNF inhibitors (TNFi) have a minor inhibitory impact on humoral SARS-CoV-2 mRNA vaccination responses. However, the impact of such immunosuppressive drugs on IgG4 switching is unknown. Aim To study the impact of widely used immunosuppressive drugs (TNFi, MTX, or the IL-4 receptor-blocking antibody dupilumab on IgG4 skewing upon repeated SARS-CoV-2 mRNA vaccination. Methods Antibody responses to the receptor-binding domain (RBD) of the spike protein upon repeated SARS-CoV-2 mRNA vaccination were measured in 604 individuals including patients with immune-mediated inflammatory diseases treated with TNFi and/or MTX, or dupilumab, as well as healthy controls and untreated patients. Results We observed a substantial increase in the proportion of RBD-specific IgG4 antibodies (median 21%) in healthy/untreated controls after a third mRNA vaccination. This IgG4 skewing was absent when primary vaccination was adenoviral vector-based and was profoundly reduced in both dupilumab- and TNFi-treated patients (<1%), but only moderately in patients treated with MTX (7%). Conclusion Our results imply a major role for both IL-4/IL-13 as well as TNF in IgG4 class switching. These novel findings advance our understanding of IgG4 class switch dynamics, and may benefit future mRNA vaccine strategies, humoral tolerance induction, as well as treatment of IgG4 pathologies.

Open article ↗



2023-02-10 | Effects of Fibulin-5 Gene Silencing on Proliferation and Apoptosis of IgG4-ROD Lacrimal Gland Fibroblasts

This study is aimed at discussing the value of RNA interference technology on inhibiting lacrimal gland fibrosis in IgG4-related ocular disease (IgG4-ROD).Six patients with IgG4-ROD who came to the hospital for surgical treatment from October 2018 to August 2019 were selected, and their diseased lacrimal glands were taken for primary cell culture and fibroblast identification. High efficiency and specificity small interference RNA (siRNA) plasmid vector was constructed, its inhibitory effect on fibroblast proliferation was determined by CCK-8 assay, and the appropriate concentration was selected as the siRNA concentration for subsequent experiments. RT-PCR and Western blot detected the relative expression levels of Fibulin-5 mRNA and protein in the cells 48 hours after transfection. The apoptosis rate of each group of cells at 24 hours, 48 hours, and 72 hours after transfection was detected by flow cytometry, and the proliferation and apoptosis of cells after silencing Fibulin-5 were analyzed and compared.24 hours after transfection, there was no significant difference in the proliferation rate among the four groups (P > 0.05); 48 hours and 72 hours after Fibulin-5 siRNA transfection, the proliferation activity of the transfected cells was significantly decreased compared with the 0 nM group, and the inhibitory effect of 75 nM siRNA was the strongest. The expression of Fibulin-5 mRNA and protein in the siRNA-transfected cells was significantly decreased compared with the blank and empty vector negative siRNA groups, and the difference was statistically significant (P < 0.05). The apoptosis rate of cells in the Fibulin-5 siRNA transfection group was significantly higher than that of cells in the blank and empty vector negative siRNA groups, and the difference was statistically significant (P < 0.05).Fibulin-5 siRNA recombinant plasmid can significantly downregulate the mRNA and protein expressions of target gene Fibulin-5 and promote apoptosis after transfection into IgG4-ROD lacrimal gland fibroblasts. It is speculated that Fibulin-5 can be used as a target to effectively inhibit the fibrosis of lacrimal gland tissues by RNAi technique.

Open article ↗



small molecules
2026-09-26 | Isolated pulmonary IgG4-related disease mimicking infection and malignancy: clinical features and a proposed diagnostic approach.

IgG4-related lung disease (IgG4-RLD) is a rare manifestation that often presents with nonspecific clinical and radiological findings, frequently mimicking pulmonary infection or malignancy. This case series aimed to characterize the clinical, serological, radiological, and pathological features of isolated pulmonary IgG4-RLD and to identify features that may facilitate its differentiation from pulmonary infection and malignancy. We reviewed a case series of patients with isolated pulmonary IgG4-RLD diagnosed at the First Affiliated Hospital of Wenzhou Medical University between April 2014 and March 2025. Clinical characteristics, laboratory findings, chest computed tomography (CT) features, histopathological findings, treatment, and follow-up data were analyzed. Eight patients with isolated pulmonary IgG4-RLD were identified. All initially presented with nonspecific respiratory symptoms and were misdiagnosed as having other pulmonary diseases, most commonly pulmonary infection. Serum IgG4 concentrations were elevated in all patients, whereas microbiological investigations and serum tumor markers were negative. Radiologically, four patients presented with solitary pulmonary lesions that frequently mimicked lung malignancy, while the remaining four had multiple lesions suggestive of pulmonary infection. Histopathological examination revealed characteristic features of IgG4-RLD, supporting the diagnosis. Following glucocorticoid-based therapy, five of six treated patients showed radiological improvement, accompanied by decreased serum IgG4 levels, while one patient remained radiologically stable during follow-up. Isolated pulmonary IgG4-RLD may mimic pulmonary infection or malignancy because of its nonspecific clinical and radiological features. Solitary lesions may raise suspicion for lung malignancy, whereas multiple lesions may be mistaken for pulmonary infection. Diagnosis requires integration of clinical, serological, radiological, and histopathological findings, with tissue biopsy playing an important role when malignancy or infection cannot be reliably excluded. Key Points • Isolated pulmonary IgG4-RLD presents with nonspecific clinical manifestations and diverse radiological features, frequently mimicking pulmonary infection or lung malignancy. • Elevated serum IgG4 levels, negative microbiological investigations, and normal tumor markers may provide important diagnostic clues in patients with suspected disease. • Histopathological examination remains the cornerstone for confirming the diagnosis of isolated pulmonary IgG4-RLD. • Recognition of the characteristic clinical, serological, radiological, and pathological features may improve the differential diagnosis.

Open article ↗



2026-09-17 | Tofacitinib for the treatment of recurrent IgG4-related disease: clinical experience in 7 patients.

This observational study aimed to evaluate the efficacy and safety of the Janus kinase (JAK) inhibitor tofacitinib in the management of recurrent IgG4-related disease (IgG4-RD). Seven patients admitted to the Rheumatology Department of Peking University People's Hospital were enrolled. All patients met the 2019 American College of Rheumatology (ACR) / European League Against Rheumatism (EULAR) classification criteria for IgG4-RD. Disease recurrence was defined as relapse of previously affected organs or involvement of new organs, accompanied by an IgG4-RD Responder Index (IgG4-RD RI) score ≥2 in any item, with or without re-elevation of serum IgG4 levels. Patients were initiated on tofacitinib 5 mg twice daily, with a concurrent increase in glucocorticoids (GCs) dosage not exceeding 10 mg (prednisone equivalent), concomitant immunosuppressants were either continued or discontinued. Clinical data were recorded at baseline, 1 month, 3 months, and every 3 months thereafter. Disease response was assessed using the IgG4-RD RI, physician global assessment (PGA) and serum IgG4 levels. Treatment responses were categorised as complete response (CR), partial response (PR), or relapse. Patients were aged 33-70 years (mean disease duration, 45 months, range 18-84 months). Six patients achieved CR, while one experienced relapse. Tofacitinib treatment for 1, 3, and 6 months resulted in a reduction in both IgG4-RD RI scores (p=0.017, p=0.018, p=0.043, respectively) and PGA scores (p=0.017, p=0.018, p=0.042, respectively). Serum IgG4 levels decreased at 3 months (p=0.028) and 6 months (p=0.043). Within 6 months of initiating tofacitinib, four out of seven patients reduced their GC dosage to ≤5 mg/day (prednisone equivalent), and two discontinued GCs during follow-up. Tofacitinib was well tolerated. Only one patient developed mild herpes zoster, and no serious adverse events were reported. Tofacitinib is effective and safe for the management of recurrent IgG4-RD, with the additional benefit of reducing GC dependence.

Open article ↗



2026-09-13 | Efficacy and safety of mycophenolate mofetil in preventing relapse of IgG4-related disease with re-elevation of serum IgG4 level during maintenance therapy: a protocol for a multicentre, randomised, double-blind, placebo-controlled study in China.

IgG4-related disease is a chronic fibroinflammatory disease with multiorgan involvement. Glucocorticoids and/or immunosuppressants as well as rituximab are both first-line treatments in remission induction therapy. However, relapse is common during the maintenance period, particularly in patients with re-elevation of serum IgG4 level. This study aims to evaluate whether adding mycophenolate mofetil (MMF) during the maintenance phase for such patients can reduce the risk of disease flare. This study is a multicentre, randomised, double-blind, placebo-controlled study. A total of 108 eligible patients with re-elevation of serum IgG4 level during maintenance therapy will be included in this study and randomised in a 1:1 ratio to receive add-on MMF 0.5 g one time per day or placebo for 52 weeks. The primary outcome is the proportion of patients experiencing relapse at week 52. Secondary outcomes include time-to-relapse, changes in disease activity and serum IgG4 level, stratified relapse rate according to the elevation level of IgG4. Analyses will follow the intention-to-treat principle. The study has been approved by the Ethics Committee of Peking Union Medical College Hospital, Chinese Academy of Medical Sciences (approval no. K3231). Written informed consent will be obtained from all participants before enrolment. Findings will be disseminated through peer-reviewed journals and conference presentations. NCT05974683.

Open article ↗



2026-09-06 | Acute coronary syndrome associated with probable immunoglobulin G4-related coronary periarteritis successfully treated with a drug-coated balloon.

Immunoglobulin G4-related disease (IgG4-RD) is a systemic inflammatory disorder that can rarely affect the coronary arteries, leading to acute coronary syndrome (ACS). A 68-year-old man with IgG4-RD presented with exertional chest pain. An electrocardiogram showing ST-segment elevation in II, III, aVF leads, and rising troponin levels confirmed ACS. Emergent coronary angiography (CAG) revealed right coronary artery occlusion, and intravascular ultrasound (IVUS) showed vasculitis-related coronary pathology. Based on these findings and the patient's clinical background, ACS secondary to IgG4-related coronary periarteritis (IgG4-related CP) was diagnosed. Because stent implantation for inflammation-associated lesions carries a high risk of restenosis, percutaneous coronary intervention (PCI) without stenting was performed. Plaque ablation was achieved using excimer laser coronary atherectomy, followed by angioplasty with a drug-coated balloon. Post-PCI coronary computed tomography angiography demonstrated perivascular soft tissue around the culprit lesion, suggestive of ongoing inflammation. Follow-up CAG and IVUS confirmed good patency without restenosis after intensification of steroid therapy. This case highlights the complexity of ACS secondary to IgG4-related CP. Coronary involvement in IgG4-RD remains under-recognized, necessitating a high index of suspicion and multimodal imaging for diagnosis. Although rare, immunoglobulin G4-related coronary involvement should be considered a potential cause of acute coronary syndrome. Awareness of this entity and a multidisciplinary, multimodality imaging-based approach, including serial coronary computed tomography and intravascular ultrasound to assess treatment response, are essential for optimal management. In cases with insufficient response to corticosteroids, additional immunosuppressive therapy may be required.

Open article ↗



2026-08-13 | Isolated IgG4-related lung disease: a case report.

IgG4-related disease (IgG4-RD) represents a chronic, immune-driven fibroinflammatory condition capable of affecting diverse organ systems; within this spectrum, pulmonary involvement (IgG4-RLD) remains comparatively uncommon. This case report outlines the clinical, imaging and pathological features of a patient with IgG4-related lung disease. We report a 60-year-old male patient with recurrent fever, chest pain, and cough with hemoptysis. Chest computed tomography (CT) initially showed right upper lobe lesions suggestive of pneumonia, but the patient failed to respond to multiple courses of antibiotics including levofloxacin, nemonoxacin malate, ceftizoxime, and amoxicillin. Further investigations revealed significantly elevated serum IgG4 level (266 mg/dL). Endobronchial ultrasound-guided transbronchial lung cryobiopsy (EBUS-GS-TBLC) confirmed dense lymphoplasmacytic infiltration in the lung tissue, with IgG4-positive plasma cells >50 per high powered field (HPF) and IgG4-positive/IgG-positive cell ratio >50%, consistent with the diagnosis of IgG4-related interstitial lung disease. The patient was treated with oral cyclosporine and mycophenolate mofetil, resulting in significant clinical and radiological improvement. IgG4-RLD should be considered in the differential diagnosis of patients with pulmonary lesions unresponsive to antibiotic therapy. Comprehensive evaluation including serum IgG4 measurement and targeted pathological biopsy is essential for accurate diagnosis. Early initiation of immunosuppressive therapy can effectively improve outcomes and prevent disease progression.

Open article ↗



antibodies
2026-09-24 | IgG4-to-IgG Ratio and Orbital Involvement Predict Clinical Response to B Cell Depletion in IgG4-Related Disease.

IgG4-related disease (RD) demonstrates ethnic variations in phenotype, but data from diverse US populations are limited. We characterized ethnic differences in organ involvement and evaluated predictors of treatment response in a multiethnic cohort. We conducted a retrospective study of 58 patients meeting 2019 American College of Rheumatology/EULAR criteria at Northwell Health (2011-2023). Data on demographics, organ involvement, histopathology, treatment, and serology (IgG4-to-IgG ratios) were analyzed. Response was assessed using Carruthers' Index. The cohort included 43.1% White, 24.1% Asian, 19.0% Hispanic, and 13.8% Black patients. Organ involvement patterns were consistent across races, with lymph nodes (22.4%), orbital/lacrimal (20.7%), and retroperitoneum (20.7%) being most affected. Higher disease burden was observed in Asian patients (1.93 vs 1.44-1.64 organs, P = 0.058). A striking disparity in rituximab use was observed (0% in Black patients vs 57%-76% in others, P = 0.002), whereas disease phenotype distribution was otherwise similar across groups. Favorable response rates were high and comparable across all racial and ethnic groups (78.6%-100%, P = 0.462). In patients treated with rituximab (n = 35), a reduction in IgG4-to-IgG ratio predicted response (area under the curve = 0.806), outperforming baseline ratios. Orbital/lacrimal involvement was strongly associated with treatment failure (75% of nonresponders vs 13.3% of responders; odds ratio 6.6, 95% confidence interval 1.4-31.9, P = 0.03). In a diverse IgG4-RD cohort, disease phenotypes were consistent across races, though treatment access disparities existed. Dynamic changes in IgG4-to-IgG ratios and the presence of orbital disease are key predictors of response to rituximab, informing personalized treatment strategies.

Open article ↗



2026-09-22 | A Rare Case of Gastritis with Prominent IgG4-Positive Plasmacytosis Mimicking IgG4-Related Gastrointestinal Disease.

IgG4-related disease (IgG4-RD) is a systemic fibroinflammatory condition characterized by dense infiltration of IgG4-positive plasma cells across multiple organs, with well-established comprehensive diagnostic criteria and organ-specific criteria. However, diagnostic standards for IgG4-related disease involving the digestive tract remain relatively new and less clearly defined. We report a case suspicious for IgG4-related gastrointestinal disease (IgG4-GID). Although a definitive diagnosis could not be established, the clinical course of the patient and our assessment based on the most up-to-date evidence warrant attention. A 40-year-old man was referred to our hospital after esophagogastroduodenoscopy revealed irregular nodules in the gastric mucosa, raising the suspicion of scirrhous-type gastric cancer. He had no significant medical history and had undergone successful eradication of Helicobacter pylori infection 5 years previously. Endoscopic examination revealed a faded shallow depression, irregular nodules, and converging folds in the gastric body. Magnifying endoscopy with narrow band imaging demonstrated a tree-like appearance with several irregular vessels, raising the suspicion of mucosa-associated lymphoid tissue (MALT) lymphoma, and a biopsy was performed. Laboratory tests showed that serum gastrin, anti-gastric parietal cell antibody, and IgG4 levels were within normal ranges. Histopathological examination showed no evidence of MALT lymphoma but revealed bottom-heavy plasmacytosis, and IgG4 immunostaining demonstrated an IgG4/IgG-positive cell ratio exceeding 40%. Endoscopic ultrasound revealed mucosal and submucosal thickening, and computed tomography (CT) showed thickening of the gastric wall, while positron emission tomography-CT showed no abnormal uptake. During the 5-year follow-up, no significant changes were observed. Biopsy also revealed neutrophilic infiltration in the superficial layer. Although IgG4-related gastritis was suspected clinically, neutrophil infiltration is uncommon in IgG4-related gastritis, and further differential diagnosis is required. This case highlights the diagnostic challenges of IgG4-rich gastric lesions and underscores the importance of distinguishing them from IgG4-GID and MALT lymphoma. When a definitive diagnosis cannot be established, careful long-term follow-up is warranted.

Open article ↗



2026-09-20 | Glucocorticoids combined with rituximab treatment for IgG4-related tubulointerstitial nephritis with diabetic nephropathy: a case report.

IgG4-related disease is a chronic immune-mediated disorder featuring elevated serum IgG4 levels and the tissue infiltration of IgG4-positive plasma cells. Kidney involvement in IgG4-related disease, known as IgG4-related kidney disease, most commonly manifests as tubulointerstitial nephritis. A 55-year-old male presented with acute kidney injury (creatinine=816 μmol/L), severe anemia, lymphadenopathy, and high IgG4 levels (13.89 g/L). Renal MRI and Chest CT showed diffuse renal abnormalities and mediastinal lymphadenopathy. Renal biopsy confirmed IgG4-related tubulointerstitial nephritis, complicated by IgA nephropathy and diabetic nephropathy. Initial glucocorticoid treatment was prescribed followed by 1.8 g rituximab consolidation therapy. Over 32 months follow-up, the patient's renal function significantly improved (creatinine 215 μmol/L) and his serum IgG4 levels normalized (0.89 g/L). This success of this case suggests that combination therapy may be a reasonable option in selected cases, and underscores the importance of an early diagnosis, pathological confirmation, and standardized immunosuppressive therapy for improving the outcomes in IgG4-related kidney disease.

Open article ↗



2026-09-15 | Diffuse Pericoronary Soft-Tissue Cuffing on Coronary Computed Tomography Angiography in a Patient with Unstable Angina: Possible IgG4-Related Coronary Periarteritis.

A 66-year-old man with hypertension, type 2 diabetes mellitus, and a 50-year smoking history was presented with acute chest pain clinically consistent with unstable angina. Coronary computed tomography angiography (CCTA) showed multivessel atherosclerosis and, more strikingly, diffuse sheath-like pericoronary soft-tissue cuffing around the major epicardial arteries-an appearance reported as the "mistletoe sign" and compatible with immunoglobulin G4 (IgG4)-related coronary periarteritis. CT-derived fractional flow reserve (CT-FFR) measured 0.75 in the left anterior descending artery, 0.68 in the left circumflex artery, and 0.94 in the right coronary artery. Invasive angiography identified a 90% proximal left circumflex stenosis as the flow-limiting lesion; drug-eluting stent implantation restored Thrombolysis in Myocardial Infarction (TIMI) grade 3 flow. Serum IgG4 (145 mg/dL) was only marginally above the diagnostic threshold, and troponin was unavailable, so the diagnosis remained clinical. Without histopathology, the findings support possible rather than definite IgG4-related disease, and the contribution of the pericoronary process to the stenosis could not be established. The patient remained stable on conventional medical therapy. CCTA, CT-FFR, and angiography answer complementary questions; diffuse pericoronary change warrants serologic and systemic evaluation for inflammatory coronary involvement, with cautious etiologic attribution.

Open article ↗



2026-08-28 | IgG4-related disease - treatment with anti-CD20, anti-CD19 antibodies, and other new drugs.

IgG4-related disease (IgG4-RD) can affect any tissue. Characteristic symptoms include tumor-like swelling of one or more organs, lymphadenopathy, involvement of the pancreatic and/or bile ducts, aortitis and retroperitoneal fibrosis, inflammatory swelling of the lacrimal or salivary glands, and nephropathy. Laboratory changes include hyperproteinemia, increased IgG4 concentration, eosinophilia, and elevated circulating plasmablasts. Presence of any of these symptoms should prompt a differential diagnosis focused on IgG4-RD. International recommendations for treatment of IgG4-RD were published in 2015, and since then, numerous studies and meta-analyses of new treatment approaches have been published. These indicate that, in 2026, the treatment of choice is monoclonal anti-CD20 antibodies, rituximab or obinutuzumab, or alternatively, the anti-CD19 antibody inebilizumab. Rituximab achieves a significantly higher number of treatment responses and has fewer side effects than the previously used prednisone, whether in monotherapy or in combination with oral immunosuppressants. However, even after rituximab treatment, the rate of early relapses is around 16-20%. Therefore, maintenance therapy with rituximab is recommended. Another approach to achieving a longer-lasting treatment response is the combination of rituximab with cyclophosphamide. In 2025, the anti-CD19 monoclonal antibody inebilizumab was approved in the United States and Europe for the treatment of IgG4-RD. It targets a broader range of B cells than rituximab and induces a longer-lasting therapeutic response. The efficacy of other drugs (obexelimab, abatacept, daratumumab, dupilumab, and others) is documented through case reports and small patient series or phase II clinical trials, and we are awaiting the results of phase III registration studies. Anti-CD20 and anti-CD19 antibodies represent the treatment of choice for IgG4-RD. They achieve a high number of complete treatment responses; however, the treatment does not end there, as it is necessary to prevent disease relapses, which are common without maintenance therapy.

Open article ↗



cell therapies
2026-01-27 | Effects of anti-CD19 CAR-T cells in a murine model of IgG4-related disease.

BACKGROUND: Chimeric antigen receptor T-cell (CAR-T) therapy, an emerging immunotherapy, has shown promising efficacy in several autoimmune diseases. In this study, we conducted a preclinical evaluation of the therapeutic potential of CD19-specific CAR-T cell–mediated B-cell depletion in a mouse model that recapitulates key features of human IgG4-related disease (IgG4-RD). METHODS: B cell depletion strategies were evaluated in the LatY136F mouse model, a spontaneous murine model of IgG4-RD. Anti-CD19 CAR-T cells or control cells were transferred into LatY136F mice pretreated with total body irradiation. LatY136F mice treated with anti-CD20 monoclonal antibodies (mAb) served as the positive control group. RESULTS: CD19-targeted CAR-T cell infusion resulted in a more profound depletion of B cells and plasmablasts compared to anti-CD20 mAb treatment. This depletion was observed in peripheral blood, spleen, lacrimal glands, lungs, and pancreas in LatY136F mice. Moreover, CAR-T cell therapy significantly prolonged the survival of LatY136F mice and improved clinical symptoms compared to anti-CD20 mAb treatment. However, while CAR-T cell therapy reduced inflammation and fibrosis in the lacrimal glands and pancreas, it did not improve these conditions in the lungs. CONCLUSIONS: Our findings demonstrate that anti-CD19 CAR-T therapy effectively alleviates the progression of IgG4-RD, showing superior efficacy compared to anti-CD20 mAb in this preclinical model. These results support further investigation of CAR-T cells as a potential therapeutic option for IgG4-RD patients, with attention to potential adverse effects.

Open article ↗



2025-12-11 | CAR T-cell therapy induces remission in multiorgan IgG4-related disease with hepatobiliary involvement.

IgG4-related disease (IgG4-RD) is a fibroinflammatory disorder in which IgG4+ B cells and T cells interact to drive chronic organ inflammation. Patients with multiorgan involvement may become refractory to standard therapy, resulting in progressive organ damage and risk of organ failure. Here, we report a patient with treatment-refractory multiorgan IgG4-RD treated with CD19-directed chimeric antigen receptor (CAR) T cells and describe the clinical and immunologic effects over more than 12 months of follow-up. A 60-year-old man with IgG4-RD involving the pancreas, hepatobiliary tract, and lungs, who was refractory to long-term immunosuppression, received autologous CD19-directed CAR T cells. Disease course was monitored longitudinally and multimodal immune profiling was performed on peripheral blood. CAR T cell therapy was well tolerated, with only grade 1 cytokine release syndrome, no neurotoxicity, and transient cytopenias without infections. Treatment induced B-cell aplasia lasting 6 months, while serum IgG4 levels normalized by month 8 and remained within the reference range thereafter. FAPI (fibroblast activation protein inhibitor) PET/CT demonstrated regression of fibroinflammatory activity, accompanied by improved lung function and quality of life. Immunosuppressive therapy was completely discontinued without disease flares for more than 12 months. B cell reconstitution consisted predominantly of naïve and transitional subsets. This was paralleled by a decline in T follicular helper cells and CD4+ cytotoxic T cells and attenuation of fibro-inflammatory and B cell-mediated signaling networks on interactome analyses. In this treatment-refractory case of multiorgan IgG4-RD, CD19-directed CAR T cell therapy induced durable, treatment-free remission with normalization of serum IgG4 and improvement across multiple clinical endpoints. Multimodal immune profiling indicates that CAR T cells can reset the B cell compartment and dampen pathogenic T cell and stromal interactions, supporting prospective evaluation of CAR T cell therapy in IgG4-RD.

Open article ↗



2025-09-20 | Heart Transplantation in Advanced Heart Failure Due to IgG4-Related Endomyocardial Fibrosis.

IgG4-related disease (IgG4-RD) is a systemic fibroinflammatory condition that rarely affects the heart. Cardiac manifestations include pericarditis, coronary arteritis, and myocarditis; endomyocardial fibrosis (EMF) is exceedingly rare. We report a 66-year-old man with advanced heart failure and recurrent hospitalizations due to restrictive cardiomyopathy, initially attributed to hypereosinophilia from parasitic disease. The patient developed cardiogenic shock requiring inotropes and intra-aortic balloon pump support. Imaging revealed biatrial enlargement, endocardial thickening, and subendocardial fibrosis, suggestive of EMF. Serology was positive for Trichinella spiralis IgG. Because of progressive clinical deterioration, the patient underwent urgent orthotopic heart transplantation. Histology of the explanted heart confirmed IgG4-related EMF. Posttransplant follow-up at 12 months showed preserved graft function and no recurrence. This case illustrates a rare cause of end-stage heart failure due to IgG4-RD and highlights the importance of including systemic inflammatory conditions in the differential diagnosis of restrictive cardiomyopathy. IgG4-related disease, though rare, can present as isolated endomyocardial fibrosis with features mimicking tropical EMF or hypereosinophilic cardiomyopathy. In advanced fibrotic stages with isolated cardiac IgG4-RD and cardiogenic shock, orthotopic heart transplantation may be the only lifesaving therapeutic option.

Open article ↗



2025-04-30 | Refractory corneal melting due to IgG4-related disease: Successful management via buccal mucosal graft transplantation.

PurposeTo present the first case of isolated corneal involvement in IgG4-RD, managed successfully with oral mucosal grafting due to the destructive course of the disease.Case reportA 56-year-old female one-eyed patient was referred to our clinic with a diagnosis of unresponsive infectious corneal melting. The ophthalmologic examination revealed light perception visual acuity, intense conjunctival inflammation and an infected area of approximately 4 × 5 mm with accompanying melting. Her medical history includes a diagnosis of dry eye disease that has persisted for over a decade, multiple previous corneal transplant surgeries in the right eye with similar complaints, and subsequent evisceration surgery. Her complaints in the left eye had increased over the previous six months, and she had undergone eight instances of amniotic membrane transplantation at an external medical facility. Corneal scraping, conjunctival and corneal biopsy were performed. The histopathologic examination and elevated serum IgG4 level indicated the presence of IgG4-related disease. She was referred to the rheumatology department, where immunosuppression treatment was initiated. Oral mucosal grafting was performed to address the uncontrolled melting. At the follow-up examination, the melting was successfully controlled, the inflammation regressed, and the early hypertrophy of the oral mucosal epithelium flattened over time.ConclusionThis case highlights the potential for IgG4-related disease to manifest as atypical ocular surface involvement. Dry eye secondary to the disease can exacerbate existing findings. In such instances, preserving the integrity of the globe is of the utmost importance. Therefore, oral mucosal grafting, which is known for its durability, should be considered a viable option.

Open article ↗



2024-12-14 | Efficacy and safety of anti-CD19 CAR-T in a mouse model of IgG4-related disease.

Dysregulated B-cell activation plays pivotal roles in IgG4-related disease (IgG4-RD), which makes B-cell depletion a potential strategy for IgG4-RD treatment. In this study, we aimed to investigate the feasibility of applying anti-CD19 chimeric antigen receptor T(CAR-T) cell therapy to IgG4-RD treatment in a mouse disease model based on LatY136F knock-in (Lat) mice. We constructed murine anti-CD19 CARs with either CD28 or 4-1BB as the intracellular costimulatory motif and evaluated the therapeutic function of the corresponding CAR-T cells by infusing them into Lat mice. Next, we assessed the safety of CAR-T infusion by evaluating the risk of cytokine release syndrome (CRS) and the antiviral capabilities in a mouse influenza infection model. Finally, we performed human anti-CD19 CAR-T manufacturing from IgG4-RD patients and evaluated its activation level and functional effects in vitro. Compared with 1D3 antibody treatment, the adoptive transfer of anti-CD19 CAR-T cells with CD28 costimulatory motif showed comparable B-cell-depletion effect in Lat mice. Furthermore, the transfer of syngeneic anti-CD19 CAR-T cells also decreased the percentage of plasma cells as well as IL-4 secreting Th cells, therefore attenuating the inflammation and fibrosis condition. CAR-T cells with CD28 costimulatory motif showed better therapeutic efficiency without the incidence of serious CRS events or increasing the risk of infection. In addition, we validated the feasibility of human CAR-T preparation in vitro from IgG4-RD patients. Taken together, these results show that anti-CD19 CAR-T therapy was effective in the treatment of a murine model of IgG4-RD, indicating its potential for clinical use in patients.

Open article ↗



proteins
2024-01-23 | Laminin 511-E8, an autoantigen in IgG4-related cholangitis, contributes to cholangiocyte protection


Abstract

Background & Aims

IgG4-related cholangitis (IRC) is the hepatobiliary manifestation of IgG4-related disease. Anti-laminin 511-E8 autoantibodies have been identified in its pancreatic manifestation. Laminin 511-E8 promotes endothelial barrier function, lymphocyte recruitment, and cholangiocyte differentiation. Here, we investigate anti-laminin 511-E8 autoantibody presence in IRC, and mechanisms via which laminin 511 may contribute to cholangiocyte protection.

Methods

Anti-laminin 511-E8 serum autoantibody positivity was assessed by ELISA. RNA sequencing and RT-qPCR were performed on human H69 cholangiocytes treated with recombinant laminin 511-E8. H69 cholangiocytes were subjected to shRNA knockdown targeting genes encoding laminin 511 (LAMA5, LAMB1, LAMC1) or treated with recombinant laminin 511-E8. Cholangiocellular bile acid influx was quantified radiochemically using 22,23-3H-glycochenodeoxycholic acid (GCDC). GCDC-induced apoptosis was determined by Caspase-3/7 assays. Cholangiocellular barrier function was assessed by FITC-dextran permeability assays. Immunofluorescent staining of laminin 511 and claudin 1 was performed on extrahepatic bile duct tissue of control and anti-laminin 511-E8 positive individuals with IRC.

Results

Seven out of 52 individuals with IRC had autoantibodies against laminin 511-E8. Recombinant laminin 511-E8 led to differential expression of genes involved in secretion, barrier function, and inflammation. Knockdown of laminin 511 constituents increased toxic bile acid permeation and GCDC-induced apoptosis. Laminin 511-E8 treatment decreased toxic bile acid permeation and dose-dependently alleviated GCDC-induced apoptosis. LAMA5 and LAMC1 knockdown increased transepithelial permeability. Laminin 511-E8 treatment reduced transepithelial permeability and prevented T lymphocyte-induced barrier dysfunction. Laminin 511 and claudin 1 staining patterns appeared altered in anti-laminin 511-E8 positive individuals with IRC.

Conclusions

Laminin 511-E8 is an autoantigen in subsets of individuals with IRC. Laminin 511 enhances cholangiocellular barrier function and protects cholangiocytes against T lymphocyte-induced barrier dysfunction, toxic bile acid permeation and bile acid-induced apoptosis.

Impact and implications

A subset of IgG4-related cholangitis (IRC) patients has autoantibodies against laminin 511-E8. In human cholangiocytes, laminin 511 protects against (T lymphocyte-induced) epithelial barrier dysfunction and hydrophobic bile acids. Laminin 511 and claudin 1 staining may be altered in extrahepatic bile ducts of anti-laminin 511-E8 positive IRC patients. This makes it tempting to speculate that a decreased epithelial barrier function with attraction of immune cells and impaired bicarbonate secretion due to dysfunction of laminin 511 by autoantibody binding could potentially be a common systemic pathogenetic mechanism in a subset of IgG4-RD patients.


Open article ↗



2022-05-19 | Role of eosinophilia in IgG4-related disease.

Immunoglobulin G4-related disease (IgG4-RD) is a heterogeneous immune-mediated condition that can affect almost any organ and is now being recognised with increasing frequency. Laboratory abnormalities including peripheral eosinophilia, hypergammaglobulinaemia, elevated serum IgE level, and hypocomplementaemia often provide initial clues to the diagnosis of IgG4-RD. The distinctive histopathological hallmarks of IgG4-RD are a dense lymphoplasmacytic infiltration with a high percentage of IgG4+ plasma cells, storiform fibrosis, obliterative phlebitis, and mild to moderate tissue eosinophilia. Around 20-40% of patients with IgG4-RD presented with peripheral eosinophilia and 51-86% are manifested as tissue eosinophilia. These data indicate an extensive involvement of eosinophil in IgG4-RD. Here, we review the biology of eosinophil, the discovery of eosinophilia in IgG4-RD, and its association with disease activity and relapse. We also discuss the possible functions and therapeutic potential of eosinophil in IgG4-RD.

Open article ↗



2022-05-13 | Central Diabetes Insipidus Due to IgG4-related Hypophysitis That Required over One Year to Reach the Final Diagnosis Due to Symptoms Being Masked by Sialadenitis

Pituitary inflammation due to IgG4-related disease is a rare condition and is sometimes accompanied by central diabetes insipidus. Central diabetes insipidus produces a strong thirst sensation, which may be difficult to distinguish when complicated by salivary insufficiency. A 45-year-old man was admitted to our department for a thorough examination of his thirst and polyuria. He had suddenly developed these symptoms more than one year earlier and visited an oral surgeon. Swelling of the left submandibular gland, right parotid gland, and cervical lymph nodes had been observed. Since his IgG4 level was relatively high at 792 mg/dL and a lip biopsy showed high plasmacytoid infiltration around the gland ducts, he had been diagnosed with IgG4-related disease. He had started taking 0.4 mg/kg/day of prednisolone, and his chief complaint temporarily improved. However, since the symptom recurred, he was referred to our institution. After admission, to examine the cause of his thirst and polyuria, we performed a water restriction test, vasopressin loading test, hypertonic saline loading test and pituitary magnetic resonance imaging. Based on the findings, we diagnosed him with central diabetes insipidus due to IgG4-related hypophysitis. We increased the dose of prednisolone to 0.6 mg/kg/day and started 10 μg/day of intranasal desmopressin. His symptoms were subsequently alleviated, and his serum IgG4 level finally normalized. We should remember that IgG4-related disease can be accompanied by hypophysitis and that central diabetes insipidus is brought about by IgG4-related hypophysitis. This case report should remind physicians of the fact that pituitary inflammation due to IgG4-related disease is very rare and can be masked by symptoms due to salivary gland inflammation, which can lead to pitfalls in the diagnosis in clinical practice.

Open article ↗



2022-03-03 | Neutralizing anti-IL-1 receptor antagonist autoantibodies induce inflammatory and fibrotic mediators in IgG4-related disease.

IgG4-related disease (IgG4-RD) is a fibroinflammatory condition involving loss of B-cell tolerance and production of autoantibodies. However, the relevant targets and role of these aberrant humoral immune responses are not defined. Our aim was to identify novel autoantibodies and autoantigen targets that promote pathogenic responses in IgG4-RD. We sequenced plasmablast antibody repertoires in patients with IgG4-RD. Representative mAbs were expressed and their specificities characterized by using cytokine microarrays. The role of anti-IL-1 receptor antagonist (IL-1RA) autoantibodies was investigated by using in vitro assays. We identified strong reactivity against human IL-1RA by using a clonally expanded plasmablast-derived mAb from a patient with IgG4-RD. Plasma from patients with IgG4-RD exhibited elevated levels of reactivity against IL-1RA compared with plasma from the controls and neutralized IL-1RA activity, resulting in inflammatory and fibrotic mediator production in vitro. IL-1RA was detected in lesional tissues from patients with IgG4-RD. Patients with anti-IL-1RA autoantibodies of the IgG4 subclass had greater numbers of organs affected than did those without anti-IL-1RA autoantibodies. Peptide analyses identified IL-1RA epitopes targeted by anti-IL-1RA antibodies at sites near the IL-1RA/IL-1R interface. Serum from patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) also had elevated levels of anti-IL-1RA autoantibodies compared with those of the controls. A subset of patients with IgG4-RD have anti-IL-1RA autoantibodies, which promote proinflammatory and profibrotic meditator production via IL-1RA neutralization. These findings support a novel immunologic mechanism underlying the pathogenesis of IgG4-RD. Anti-IL-1RA autoantibodies are also present in a subset of patients with SLE and RA, suggesting a potential common pathway in multiple autoimmune diseases.

Open article ↗



2021-10-13 | Interleukin-35 promotes the differentiation of regulatory T cells and suppresses Th2 response in IgG4-related type 1 autoimmune pancreatitis.

IgG4-related disease (IgG4-RD) is a systemic inflammatory disease, which includes type 1 autoimmune pancreatitis (AIP). Interleukin-35 (IL-35) exhibits immunosuppressive effects in several autoimmune diseases. However, the expression of IL-35 had not been reported so far in type 1 AIP. We evaluated the association between IL-35 and several cytokines, which mediate the function of Tregs in type 1 AIP. Plasma was collected from patients with type 1 AIP, alcoholic chronic pancreatitis (ACP), and healthy controls (HC) and assayed for cytokine expression. Total mRNA separated from peripheral blood was isolated from naïve Tregs (nTregs) and effector Tregs (eTregs). EBI3 and IL-12p35 gene expressions were tested in these cells by quantitative PCR. In addition, expression of IL-35 subunits in the pancreatic tissues of patients with type 1 AIP and ACP was analyzed by immunohistochemistry. IL-35 was significantly elevated in type 1 AIP (n = 32) plasma compared with ACP (n = 16) and HC (n = 22), but IL-27 was not. We also detected many cells expressing both EBI3 and IL-12p35 in type 1 AIP tissues. Moreover, in peripheral blood lymphocyte, the percentage of nTregs and eTregs of CD4+ T cells in patients with type 1 AIP (n = 14) compared with HC (n = 15) was significantly decreased and increased, respectively. There were no significant differences of gene expression in patients with type 1 AIP and HC. This study identified elevated expression of plasma IL-35 and tissue IL-35 subunits in patients with type 1 AIP. This might lead to inflammation suppression via activated eTregs. IL-35 might be associated with this anti-inflammatory role, especially against the Th2 response through several cytokines and the differentiation of Tregs in type 1 AIP.

Open article ↗



other
2025-07-08 | A case of IgG4-related disease potentially triggered by COVID-19 vaccination: longitudinal serum IgG4 monitoring from prevaccination.

We report a case of a 64-year-old Japanese man who developed IgG4-related pericoronary arteritis following mRNA-based COVID-19 vaccination. The patient presented with anterior chest pain and imaging revealed perivascular soft tissue thickening around the coronary arteries, along with pancreatic enlargement, enlarged prostate, and periaortitis. Laboratory tests showed markedly elevated serum IgG4 levels (1740 mg/dl). Histopathological findings from prostate biopsy were consistent with IgG4-related disease. Notably, retrospective analysis of preserved serum samples demonstrated a sharp increase in IgG4 levels following the third BNT162b2 vaccine dose, suggesting a possible link between vaccination and disease onset. The patient responded to prednisolone, with significant clinical and radiological improvement. However, IgG4 levels rebounded during tapering, requiring additional immunosuppressive therapy with azathioprine and planned rituximab treatment. This case represents the first documented instance tracking longitudinal changes in serum IgG4 levels from prevaccination through disease onset. While a definitive causal relationship between COVID-19 vaccination and IgG4-related disease remains unproven, this case highlights the need for further investigation into the potential immunopathogenic mechanisms involved.

Open article ↗



2023-10-02 | Suppressed IgG4 class switching in dupilumab- and TNF inhibitor-treated patients after repeated SARS-CoV-2 mRNA vaccination

Abstract Background Repeated mRNA vaccination against SARS-CoV-2 has been shown to induce class switching to IgG4, a non-inflammatory human antibody subclass linked to tolerance. Although poorly understood, prolonged antigenic stimulation and IL-4 signalling may be instrumental in IgG4 switching. We and others have previously shown that widely used immunosuppressive drugs such as methotrexate (MTX) and TNF inhibitors (TNFi) have a minor inhibitory impact on humoral SARS-CoV-2 mRNA vaccination responses. However, the impact of such immunosuppressive drugs on IgG4 switching is unknown. Aim To study the impact of widely used immunosuppressive drugs (TNFi, MTX, or the IL-4 receptor-blocking antibody dupilumab on IgG4 skewing upon repeated SARS-CoV-2 mRNA vaccination. Methods Antibody responses to the receptor-binding domain (RBD) of the spike protein upon repeated SARS-CoV-2 mRNA vaccination were measured in 604 individuals including patients with immune-mediated inflammatory diseases treated with TNFi and/or MTX, or dupilumab, as well as healthy controls and untreated patients. Results We observed a substantial increase in the proportion of RBD-specific IgG4 antibodies (median 21%) in healthy/untreated controls after a third mRNA vaccination. This IgG4 skewing was absent when primary vaccination was adenoviral vector-based and was profoundly reduced in both dupilumab- and TNFi-treated patients (<1%), but only moderately in patients treated with MTX (7%). Conclusion Our results imply a major role for both IL-4/IL-13 as well as TNF in IgG4 class switching. These novel findings advance our understanding of IgG4 class switch dynamics, and may benefit future mRNA vaccine strategies, humoral tolerance induction, as well as treatment of IgG4 pathologies.

Open article ↗



2023-02-10 | Effects of Fibulin-5 Gene Silencing on Proliferation and Apoptosis of IgG4-ROD Lacrimal Gland Fibroblasts

This study is aimed at discussing the value of RNA interference technology on inhibiting lacrimal gland fibrosis in IgG4-related ocular disease (IgG4-ROD).Six patients with IgG4-ROD who came to the hospital for surgical treatment from October 2018 to August 2019 were selected, and their diseased lacrimal glands were taken for primary cell culture and fibroblast identification. High efficiency and specificity small interference RNA (siRNA) plasmid vector was constructed, its inhibitory effect on fibroblast proliferation was determined by CCK-8 assay, and the appropriate concentration was selected as the siRNA concentration for subsequent experiments. RT-PCR and Western blot detected the relative expression levels of Fibulin-5 mRNA and protein in the cells 48 hours after transfection. The apoptosis rate of each group of cells at 24 hours, 48 hours, and 72 hours after transfection was detected by flow cytometry, and the proliferation and apoptosis of cells after silencing Fibulin-5 were analyzed and compared.24 hours after transfection, there was no significant difference in the proliferation rate among the four groups (P > 0.05); 48 hours and 72 hours after Fibulin-5 siRNA transfection, the proliferation activity of the transfected cells was significantly decreased compared with the 0 nM group, and the inhibitory effect of 75 nM siRNA was the strongest. The expression of Fibulin-5 mRNA and protein in the siRNA-transfected cells was significantly decreased compared with the blank and empty vector negative siRNA groups, and the difference was statistically significant (P < 0.05). The apoptosis rate of cells in the Fibulin-5 siRNA transfection group was significantly higher than that of cells in the blank and empty vector negative siRNA groups, and the difference was statistically significant (P < 0.05).Fibulin-5 siRNA recombinant plasmid can significantly downregulate the mRNA and protein expressions of target gene Fibulin-5 and promote apoptosis after transfection into IgG4-ROD lacrimal gland fibroblasts. It is speculated that Fibulin-5 can be used as a target to effectively inhibit the fibrosis of lacrimal gland tissues by RNAi technique.

Open article ↗



Access all drug discovery papers and probability of success in trials forecasts:

Access all drug discovery papers and probability of success in trials forecasts:

Drug Discovery Landscape

5 orphan drug designations for IgG4-related disease, including 1 approved therapy.

5 orphan drug designations for IgG4-related disease, including 1 approved therapy.

Drug

Therapy type

Orphan designation

Clinical trial status

Sponsor

inebilizumab-cdon [Uplizna]

antibodies

FDA
2026-05-01

Approved
2025-04-03

Horizon Therapeutics Ireland DAC

Rilzabrutinib

small molecules

EMA
2025-08-22

Phase III
Ongoing

Sanofi B.V.

rilzabrutinib

small molecules

FDA
2025-04-01

Phase III
Ongoing

Sanofi US Services, Inc

Humanised Fc-engineered monoclonal antibody against CD19

antibodies

EMA
2018-01-17

Phase III
Ongoing

Zenas BioPharma B.V.

obexelimab

antibodies

FDA
2017-05-09

Phase III
Ongoing

Zenas BioPharma (USA) LLC.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.